This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to French - Rates: 0.07 - 0.12 EUR per word / 30 - 40 EUR per hour French to English - Rates: 0.07 - 0.12 EUR per word / 30 - 40 EUR per hour Spanish to French - Rates: 0.07 - 0.12 EUR per word / 30 - 40 EUR per hour Spanish to English - Rates: 0.07 - 0.12 EUR per word / 30 - 40 EUR per hour
Access to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
English to French: Still Life (Poetry in English) General field: Art/Literary Detailed field: Poetry & Literature
Source text - English 1 - Still Life
I
drifted into
schizo consciousness.
Eyes closed,
hands crossed,
the curtain''s
drawn.
Beyond the pane,
a few thin shadows roam,
on this motionless bridge,
transfixed with the still rage
of self effacing souls.
Eyes of weeping willows
etch impalpable shadows,
sketch an impossible cry,
extracted from sorrow,
exempt of intent,
or want of ''I''.
Stilllife – Copyright@1991valeriemarzac
Translation - French 1 - Still Life
I
drifted into
schizo consciousness.
Eyes closed,
hands crossed,
the curtain''s
drawn.
Beyond the pane,
a few thin shadows roam,
on this motionless bridge,
transfixed with the still rage
of self effacing souls.
Eyes of weeping willows
etch impalpable shadows,
sketch an impossible cry,
extracted from sorrow,
exempt of intent,
or want of ''I''.
Stilllife – Copyright@1991valeriemarzac
English to French: S...inequanon (English) Editor’s Choice Award-poetry.com) General field: Art/Literary Detailed field: Poetry & Literature
Source text - English S...inequanon Editor’s Choice Award-poetry.com)
I am inhabited by an Absolute Sun
of cosmic sparks and dazzling toxins.
What an embrace! These blossoming kisses!
How they flourish in the folds of sunset,
enlacing me to my final season.
See this raft of reed and ivy?
How it weaves its devotional web!
How it fondly flows and ebbs
to cajole my confounded self.
Sustain me through, oh, my Kindred Spirit!
Elated, don''t my senses astound you? My kindled ghost
Reborn, gasping for your fated lips, my Oracle.
God - manifest in the exalted nest of your soul,
Intensely dear, the essence of ardor - My wish treasure,
Oh, agonizing in the ostensible tentacles of its founder.
Stilllife – Copyright@2008valeriemarzac
Translation - French S...inequanon (Editor’s Choice Award -poetry.com)
I am inhabited by an Absolute Sun
of cosmic sparks and dazzling toxins.
What an embrace! These blossoming kisses!
How they flourish in the folds of sunset,
enlacing me to my final season.
See this raft of reed and ivy?
How it weaves its devotional web!
How it fondly flows and ebbs
to cajole my confounded self.
Sustain me through, oh, my Kindred Spirit!
Elated, don''t my senses astound you? My kindled ghost
Reborn, gasping for your fated lips, my Oracle.
God - manifest in the exalted nest of your soul,
Intensely dear, the essence of ardor - My wish treasure,
Oh, agonizing in the ostensible tentacles of its founder.
Stilllife – Copyright@2008valeriemarzac
English to French: Medical General field: Medical
Source text - English Overall time to virologic failure*
Baseline
Persons at risk, n
48 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
96 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
Difference in 96-wk Kaplan–Meier estimate (95% CI), percentage points
Full follow-up
Events/total person-years at risk, n/n
Estimated HR (95% CI)‡
Screening HIV RNA level 100 000 copies/mL
Baseline
Persons at risk, n
48 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
96 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
Difference in 96-wk Kaplan–Meier estimate (95% CI), percentage points
Full follow-up
Events/total person-years at risk, n/n
Estimated HR (95% CI)‡
Time to primary safety end point§
Baseline
Persons at risk, n
48 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
96 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
Difference in 96-wk Kaplan–Meier estimate (95% CI), percentage points;
P value
Full follow-up
Events/total person-years at risk, n/n
Estimated HR (95% CI); P value‡||
Time to primary tolerability end point¶
Baseline
Persons at risk, n
48 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
96 wk
Events/persons at risk (Kaplan–Meier estimate), n/n (%)†
Difference in 96-wk Kaplan–Meier estimate (95% CI), percentage points;
P value
Full follow-up
Events/total person-years at risk, n/n
Estimated HR (95% CI); P value‡||
DF = disoproxil fumarate; HR = hazard ratio.
* Time to virologic failure: all participants analyzed as randomly assigned, and follow-up was included regardless of treatment status.
† Kaplan–Meier estimates are presented as cumulative probability of having the event by the given week.
‡ HRs were estimated with Cox proportional hazards models, and stratified by screening viral load strata for overall comparisons.
§ Time to first primary safety end point (first grade-3 or -4 sign, symptom, or laboratory abnormality while patients were receiving the originally assigned third drug [atazanavir plus ritonavir or efavirenz] that was ≥1 grade higher than baseline, excluding isolated unconjugated hyperbilirubinemia and creatine kinase).
|| P value from a log-rank test stratified by screening viral load group.
¶ Time to primary tolerability end point (first change in therapy, ignoring nucleoside reverse transcriptase inhibitors).
1.22 (0.70 to 2.11)
Appendix Table 2.
Summary of Sensitivity Analyses for Atazanavir Plus Ritonavir Versus Efavirenz, With Efavirenz as the Reference in All Comparisons
Outcome
End Point Description
Result Summary
Estimated Hazard Ratio (95% CI)*
Abacavir– Lamivudine
Tenofovir DF–Emtricitabine
Time to virologic failure
Time to safety event‡
Time to tolerability event
Primary efficacy end points plus potential virologic failures without confirmation sample (unconfirmed failures [n = 34]); all follow-up included, and patients were analyzed per originally assigned regimen
Primary efficacy end points plus unconfirmed failures, premature study discontinuation, and deaths; all follow-up included, and patients were analyzed per originally assigned regimen
Primary efficacy end points that occurred while receiving the originally assigned third drug; patients are censored from follow-up time at the first modification of the assigned third drug
Primary efficacy end points that occurred while receiving the originally assigned regimen; patients are censored from follow-up time at the first modification of the assigned third drug or NRTI
Primary efficacy end point, in which the high viral load stratum is censored at the time of the DSMB action; all follow-up is included for the low viral load stratum, and patients are analyzed per originally assigned regimen
Primary safety end points that occurred while receiving the originally assigned regimen (third drug and NRTI); patients are censored from follow-up time at the first modification of the assigned third drug or NRTI; this was the primary safety end point before the DSMB decision
Primary safety end points that occurred during the study; all follow-up included, and patients were analyzed per originally assigned regimen; signs or symptoms and laboratory data were collected throughout study follow-up regardless of regimen status; this end point was reviewed by the DSMB
Translation - French Délai jusqu'à l'échec virologique
Initial
Personnes à risque, n
48 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
96 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
Différence en estimation Kaplan–Meier à 48 sem. (IC 95 %), pour cent
Suivi complet
Evénements / total personne-années à risque, n/n
RR estimé (IC 95 %)
Taux initiaux d'ARN du VIH-1 < 100 000 copies / mL
Initial
Personnes à risque, n
48 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
96 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
Différence en estimation Kaplan–Meier à 48 sem. (IC 95 %), pour cent
Suivi complet
Evénements / total personne-années à risque, n/n
RR estimé (IC 95 %)
Taux initiaux d'ARN du VIH-1 > 100 000 copies / mL
Initial
Personnes à risque, n
48 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
96 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
Différence en estimation Kaplan–Meier à 96 sem. (IC 95 %), pour cent
Suivi complet
Événements / total personne-années à risque, n/n
RR estimé (IC 95 %)‡
Délai jusqu'au critère principal d'innocuité§
Initial
Personnes à risque, n
48 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
96 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
Différence en estimation Kaplan–Meier à 96 sem. (IC 95 %), pour cent
Valeur de P
Suivi complet
Evénements / total personne-années à risque, n/n
RR estimé (IC 95 %), valeur de P‡||
Délai jusqu'au critère principal de tolérabilité¶
Initial
Personnes à risque, n
48 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
96 sem.
Événements / personnes à risque (estimation Kaplan–Meier), n/n (%)†
Différence en estimation Kaplan–Meier à 96 sem. (IC 95 %), pour cent
Valeur de P
Suivi complet
Événements / total personne-années à risque, n/n
RR estimé (IC 95 %), valeur de P‡||
DF = disoproxil fumarate; RR = risque relatif.
* Délai jusqu'à l'échec virologique : tous les participants étaient analysés selon la randomisation attribuée, et le suivi était inclus sans tenir compte du statut de traitement.
† Les estimations de Kaplan–Meier sont présentées comme la probabilité cumulée de survenue de l’événement une semaine donnée.
‡ Les RR étaient estimés dans un modèle de hasards proportionnels de Cox et stratifiés selon la charge virale initiale pour l'ensemble des comparaisons.
§ Délai jusqu'au premier critère d'innocuité (premier signe, symptôme ou anomalie biologique de grade 3 ou 4 durant la période de traitement avec le 3ème médicament attribué au départ [atazanavir plus ritonavir ou éfavirenz] qui augmentait d'1 gradation ou plus par rapport à l'évaluation initiale, en excluant l'élévation isolée de la bilirubine non conjuguée et de la créatine kinase).
|| Valeur de P d'après un test de log-rank stratifié selon la charge virale initiale
¶ Délai jusqu'au critère principal de tolérabilité (premier changement de traitement, sans tenir compte des inhibiteurs nucléosiques de la transcriptase inverse).
1,22 (0,70 à 2,11)
Appendice tableau 2.
Résumé des analyses de sensibilité pour Atazanavir Plus Ritonavir Versus Éfavirenz, avec Éfavirenz comme Référence dans toutes les Comparaisons
Devenir
Description du critère
Résumé du résultat
Risque Relatif Estimé (IC 95 %)*
Abacavir– Lamivudine
Ténofovir DF–Emtricitabine
Délai jusqu'à l'échec virologique
Délai jusqu'à événement d'innocuité
Délai jusqu'à événement de tolérabilité
Critères d'efficacité principaux plus échecs virologiques potentiels sans échantillon de confirmation (échecs non confirmés [n = 34]), tous les suivis inclus, et les patients étaient analysés par traitement attribué au départ
Critères d'efficacité principaux plus échecs virologiques non confirmés, interruption prématurée de l'étude, et décès, tous les suivis inclus, et les patients étaient analysés par traitement attribué au départ
Critères d'efficacité principaux survenus pendant le traitement par le 3ème médicament attribué au départ, les patients sont censurés à partir du moment du suivi à la première modification du 3ème médicament attribué
Critères d'efficacité principaux survenus pendant le traitement attribué au départ, les patients sont censurés à partir du moment du suivi à la première modification du 3ème médicament ou du INTI attribué
Critère d'efficacité principal, dans lequel la strate de charge virale élevée est censurée au moment de la revue par le DSBM, tout suivi est inclu pour la strate de charge virale inférieure, et les patients étaient analysés par traitement attribué au départ
Critères d'efficacité principaux survenus pendant le traitement attribué au départ (3ème médicament et INTI), les patients sont censurés à partir du moment du suivi à la première modification du 3ème médicament ou de l’INTI attribué, ceci était le critère principal d'innocuité avant la décision du DSMB
Critères d'efficacité principaux survenus durant l'étude, tous les suivis inclus, et les patients étaient analysés par traitement attribué au départ, les signes ou symptômes et les données biologiques étaient recueillis durant le suivi de l'étude sans tenir compte du statut de traitement, ce critère a été revu par le DSBM
French to English (CAPES English Teacher &Published Writer) English to French (CAPES in English (National Competitive Teaching Ex) English to French (MAITRISE in English Linguistics & Translation) English to French (LICENSE (Degree) in English Linguistics, Translati)
Memberships
N/A
Software
Adobe Acrobat, Microsoft Excel, Microsoft Office Pro, Microsoft Word, Audacity, Cubase, Cyberlink PowerDirector IOS, Music Maker, Smule, Powerpoint, Smartcat, Trados Studio
Help or teach others with what I have learned over the years
Bio
Why should you need me? Are you looking
for a qualified and experienced translator? Wouldn’t it be even better if this
translator was truly bilingual? And even better, what if this translator was
also a published writer? But how much would this cost? What if you could find
all of the above for a very reasonable rate? It would give you peace of mind
and help make sure that your clients come back for more first class work.
And this is where I come in. I'm Valérie Marzac. Please to meet you! I'm
a fully bilingual English & French Translator with 27 years of experience.
I first became an English Teacher after studying as a post grad for 5 years at
university in France. This allowed me to perfect my knowledge and skills in
translation, linguistics and literature. I was born in France to English
professors. I learnt English as a child and lived in England for about 10 years
and in the US for about 5 years. I'm naturally bilingual.
Did you know that when you're fully bilingual, your personality changes
depending on which language you speak? I have always been fascinated by this.
And so I became a translator in 1997. I love writing, analysing and conveying any
message in the best possible manner. I also translate from Spanish and I speak some Egyptian Arabic
and German.
It stands to reason that a translation can never be literal. Take
English and French for instance. English is analytical while French is
synthetical. Yes, this is the reason why an English dictionary is about twice
as big!
I also enjoy writing and translating song
lyrics, transcription, and also text to audio because I happen to have a pleasant
voice which allows me to do voice-over work, sing and make my own videos on
YouTube and also talk on social networks, mostly to help others, sometimes to
teach them English. I love making my own organic products, walking in the
French countryside, and spending time with my dog. I have a keen interest in philosophy
and the medical world. Did I mention that I love cars and fashion as well as helping
others and doing my best?
Send me a message and let’s get the work done in the
timeframe allocated to your project!
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Expertise